[Infections of the musculoskeletal system with chronic polyarthritis during a combination therapy with Methotrexate

K S Delank1, T Hansen, P Eysel

  • 1Orthopädische Universitätsklinik Köln, Germany. Karl-Stefan.Delank@medizin.uni-koeln.de

Abstract

Insights

The combination of Methotrexate and Leflunomide for rheumatoid arthritis may increase the risk of serious musculoskeletal infections, particularly in bone surgery patients. Caution is advised when using these immune-modulating drugs together.

Area of Science:

  • Rheumatology
  • Orthopaedic Surgery
  • Infectious Disease

Background:

  • Conventional disease-modifying antirheumatic drugs (DMARDs) show unsatisfactory long-term results for rheumatoid arthritis.
  • Combination therapy with Methotrexate (MTX) and Leflunomide is increasingly used.
  • The impact of these immune-modulating drugs on perioperative infection rates remains debated.

Observation:

  • A study evaluated 16 patients undergoing orthopaedic surgery on MTX/Leflunomide combination therapy over 1.5 years.
  • Three patients (18.75%) developed severe musculoskeletal infections during the observation period.

Findings:

  • The combination of MTX and Leflunomide may be associated with an increased risk of serious infections.
  • Synergistic effects on both therapeutic outcomes and side effects are possible.
  • This finding contrasts with previous reports suggesting no increased infection risk.

Implications:

  • Clinicians should exercise caution when prescribing MTX/Leflunomide combination therapy, especially for patients undergoing bone surgery.
  • Further research is needed to fully elucidate the infection risks associated with this drug combination.
  • This highlights the importance of monitoring for infections in patients on combined immune-modulating therapy.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...